Abcodia | detecting cancer earlier
detecting cancer earlier

Follow us



Despite advances in diagnosis and treatment, cancer remains a highly lethal disease with as many as 14.2 million new cancer cases and 8.2 million deaths reported annually worldwide. Research shows that the earlier cancer can be detected, the better the survival prospects. However, few tests can accurately detect cancer before symptoms appear.

Abcodia, together with our partners and collaborators, are engaged in the clinical and commercial development of novel, scientifically validated tests for the early detection of several cancers. In 2013 Abcodia formed an alliance with Cancer Research UK to discover and validate blood-based biomarkers that may be used in the earlier detection of pancreatic, lung, colorectal and oesophageal cancers. more...


Abcodia's first screening product, the ROCA® Test, determines the likelihood of a woman having having ovarian cancer - even before symptoms appear. In clinical studies of patients in the general population, the ROCA Test along with appropriate clinical follow up, has been shown to detect more than twice as many ovarian cancers as tests that use a fixed CA125 cutoff.

The ROCA Test is CE marked and is available in the private healthcare market in the U.K. and is available in select U.S. markets. For more information about the most proven method of screening for ovarian cancer, visit



Between 2001 and 2005 202,638 women volunteers were enrolled into the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Volunteers donated serum samples for up to 10 years. The resulting biobank contains over 5 million straws of serum representing all diseases. These prospective longitudinal samples are rare and ideal for use in the development of biomarkers for the earlier detection of disease.

Abcodia has the exclusive commercial rights to this biobank and uses these samples for internal research and development and provides samples under license for use in the third party projects.


Abcodia Announces Expanded U.S. Availability of the ROCA® Test for Early Ovarian Cancer Detection to 15 States and the District of Columbia

Abcodia, a commercial stage company focused on the development of proprietary tests for the early detection of cancer, today announced expanded U.S. availability of the ROCA® Test. Following an initial U.S. launch in Arizona, Illinois, Massachusetts, New Jersey and Texas, the ROCA Test is now available in nine additional states (Georgia, Michigan, Missouri, North Carolina, Nevada, Ohio, Oregon, Virginia, Washington, Wisconsin) and the District of Columbia. More...

Abcodia ROCA® Test now offered nationwide by the UK’s largest private health group, BMI Healthcare

Abcodia announced today that its ovarian cancer detection tool, the ROCA® Test, will be offered by BMI Healthcare. The multimodal screening test provides new hope for women with ovarian cancer through earlier detection of the disease, which may prevent one in five deaths, as shown in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) study. BMI Healthcare becomes the first UK-wide provider of the ROCA Test. More...